CEO of Pattern Pharma, which is taking its plant-derived immunotherapeutic through the FDA approval process as a botanical drug

Co-founder & CEO of an innate immunity company (Petrovax) which was successfully sold and whose approved product is in widespread use
Director of business development at a pharma multinational (GSK)
Co-founder of a NASDAQ-listed biotech (Milestone) and co-founder of a biopharma company (Mimetogen)
Founder of a VC fund (iNovia Capital, now having >$1B AUM) which he ran for ten years

Postdoctoral research at the Institute for Advanced Study in Princeton

DPhil in Physics from Oxford University

MSc from the University of Toronto.